Tvardi Therapeutics, Inc. (TVRD) stock

TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30

$1.18+0.02 (+2.16%)

Close on Nov 13, 2026Market cap $15.74MP/E –Yield 0.00%

Tvardi Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Tvardi Therapeutics's EV/EBITDA was 67.4× on Jan 31, 2022, against 313.0× a year earlier.

Period	Period end	Value	Change (pts)
2022	Jan 31, 2022	67.4×	−3.9
2021	Dec 31, 2021	71.4×	−241.6
2014	Apr 30, 2014	313.0×	–

See a number that looks wrong?